Business Context and Reporting Period
This Form 8-K filing by Dare Bioscience, Inc. (DARE) covers the event date of November 26, 2025. The report details the termination of a material definitive agreement with Bayer HealthCare LLC regarding the development and commercialization of the contraceptive product Ovaprene in the U.S.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, or cash flow data for a reporting period. However, it discloses specific financial implications of the agreement termination:
- Revenue Recognition: The Company will record the previously received $1.0 million upfront non-refundable license fee from Bayer as license revenue upon the effective termination of the agreement.
- Future Revenue Impact: The Company will not receive any future license fees, milestone payments, or other payments from Bayer.
- Liquidity and Funding: The ongoing pivotal Phase 3 clinical study is supported by grant funding received in November 2024.
Material Changes
The primary material change is the termination of the License Agreement dated January 10, 2020, between Dare Bioscience and Bayer. Key details include:
- Effective Date: Termination will be effective 90 days after the notice date, on February 24, 2026.
- Reason: Bayer cited strategic prioritization as the reason for termination.
- Operational Impact: All licenses and rights granted to Bayer will terminate. Bayer will cease providing expert support for clinical, regulatory, and commercial matters.
- Study Continuity: Dare Bioscience states it does not expect the termination to materially impact the ongoing pivotal Phase 3 clinical study of Ovaprene (NCT06127199).
Outlook, Risks, and Management Commentary
Management Commentary and Outlook:
- The Data Safety Monitoring Board (DSMB) recommended in July 2025 that the Phase 3 study continue without modification.
- Active recruitment is being maintained at five study sites.
- Enrollment is currently anticipated to be completed in 2026.
Risks and Contingencies:
- Capital Needs: The filing highlights risks related to the ability to raise additional capital to execute business strategy and continue as a going concern.
- Grant Dependence: The Company notes dependence on grants from governmental entities and the Gates Foundation, which can be modified or terminated at the funder's discretion.
- Clinical Trial Risks: Standard risks include the ability to enroll sufficient patients, meet clinical endpoints, and avoid safety concerns.
- Commercialization: Risks include inexperience in commercializing products and market acceptance.
Investor Verification Checklist
- Verify the exact timing of the $1.0 million revenue recognition in the next quarterly filing.
- Confirm the status of the November 2024 grant funding and its sufficiency to cover the Phase 3 trial through 2026.
- Monitor enrollment rates for the Ovaprene Phase 3 study to ensure the 2026 completion target remains viable without Bayer's support.
- Review upcoming filings for any updates on the Company's cash runway and capital raising activities.
- Check for any changes in the Data Safety Monitoring Board's recommendations following the termination.